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BACKGROUND: The use of brand rather than generic
names for medications can increase health care costs.
However, little is known at a national level about how
often physicians refer to drugs using their brand or
generic names.
OBJECTIVE: To evaluate how often physicians refer to
drugs using brand or generic terminology.
DESIGN AND PARTICIPANTS: We used data from the
2003 National Ambulatory Medical Care Survey
(NAMCS), a nationally representative survey of 25,288
community-based outpatient visits in the United
States. After each visit, patient medications were
recorded on a survey encounter form by the treating
physician or transcribed from office notes.
MEASUREMENTS: Our main outcome measure was
the frequency with which medications were recorded on
the encounter form using their brand or generic names.
RESULTS: For 20 commonly used drugs, the median
frequency of brand name use was 98% (interquartile
range, 81–100%). Among 12 medications with no
generic competition at the time of the survey, the
median frequency of brand name use was 100% (range
92–100%). Among 8 medications with generic competi-
tion at the time of the survey (“multisource” drugs), the
median frequency of brand name use was 79% (range
0–98%; P<.001 for difference between drugs with and
without generic competition).
CONCLUSIONS: Physicians refer to most medications
by their brand names, including drugs with generic
formulations. This may lead to higher health care costs
by promoting the use of brand-name products when
generic alternatives are available.
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INTRODUCTION
Brand name drugs are often dispensed when bioequivalent
generic alternatives are available, resulting in an estimated
$8.8 billion in excess expenditures per year in the United
States.
1 This potentially unnecessary use of brand name drugs
may reflect physician and patient beliefs that brand name
drugs are superior to their generic counterparts.
2 However,
habitual use of brand name terminology may also play an
important role in the dispensing of brand-name products, as
the name recorded on a prescription can impact whether a
drug is dispensed in brand or generic form even when the
physician would accept the generic version, and the pharmacy
is empowered to provide it.
3,4
We used data from a large, nationally representative sample
of outpatient visits to evaluate how frequently brand and
generic name equivalents are used in clinical practice.
METHODS
We used data from the 2003 National Ambulatory Medical
Care Survey (NAMCS), a nationally representative survey of
25,288 community-based office visits to 1,342 physicians in
the United States.
5 After each sampled visit, forms were
completed by the treating physician or by office staff and/or
survey field representatives (who abstracted information ver-
batim from the medical record to the survey form). All
medications (up to 8) prescribed or continued at the visit were
recorded and subsequently entered into the NAMCS database
using separate numeric codes corresponding to the name
written on the form and to the drug’s nonproprietary name.
The route of administration is not specified in NAMCS;
therefore, oral, topical, and other forms of the same compound
were encoded using a single identifier.
We determined the 20 most frequently mentioned prescrip-
tion medications in NAMCS, excluding vaccinations, combina-
tion products, and medications typically administered in the
office setting. To avoid biasing this list toward specialties that
prescribed and/or recorded many drugs, in this step we
calculated drug frequencies based only on the first medication
listed on the study form. Next, for each of the 20 drugs, we
assessed the frequency of each name that the physician or
assistant had recorded on the form (e.g., for atorvastatin, the
frequency of mentions of “atorvastatin” and “Lipitor”). In this
step we searched all 8 medication fields.
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645In all analyses, we adjusted for sampling probability and
clustering effects to create nationally representative estimates
for each drug present at the clinic visit.
6 Because numerous
survey strata contained a single primary sampling unit, we
performed our analyses without adjustment for stratification.
This preserves the original point estimate while producing
slightly wider confidence intervals around that estimate.
Finally, we searched the Food and Drug Administration
(FDA) “Electronic Orange Book” (http://www.fda.gov/cder/
ob/docs/queryai.htm) and supplemental sources to assess
the presence of generic competition for each of the 20 drugs.
We considered the date of FDA approval for the first generic
formulation (in any dose or route of administration) to be the
time at which generic alternatives became available. This
research was exempted from review by the institutional review
boards of the San Francisco VA Medical Center and the
University of California, San Francisco.
RESULTS
At least one medication was recorded in 66% of visits. The
majority (89%) of these visits occurred in private solo or group
practice settings, with the most common specialties being
general or family physicians (25%), primary care internists
(16%), pediatricians (10%), and obstetrician–gynecologists
(9%). Survey forms were completed by physicians in 16% of
visits, by office staff in 34%, by census field representatives in
29%, by multiple personnel in 18%, and by other or unrecord-
ed sources in 3%.
The 20 most commonly recorded medications are listed in
Table 1. Overall, the median frequency of brand name use
was 98% (interquartile range, 81–100%), and ranged from 0–
100% of drug mentions. Among the 12 medications with no
generic competition at the time of the survey, the median
frequency of brand name use was 100% (range 92–100%).
Among the 8 medications with generic competition at the
time of the survey, the median frequency of brand name use
was 79% (range 0–98%). This difference was statistically
significant (P<.001).
Because office staff and census field workers completed the
majority of forms, we performed additional analyses to evaluate
if the proportion of brand versus generic names recorded by
physicians differed from the proportion recorded by nonphysi-
cians. For 18 of 20 medications, there were no significant
differences between physicians and nonphysicians in the use of
brand versus generic names (P>=.10 for each). The two
exceptions were azithromycin (brand name used by 92% of
physicians vs 98% of nonphysicians, P=.09) and prednisone
(brand name used by 4% of physicians vs 0% of nonphysicians,
P=.002).
DISCUSSION
In this nationally representative survey, physicians referred to
medications by their brand names much more frequently than
by their generic names. Brand names were used almost
exclusively for drugs without generic competition at the time
of the survey. Brand name use was also common for drugs
with generic competition, although at lower rates and with
greater variability between drugs. While to our knowledge no
previous studies have evaluated the use of drug terminology on
a national scale, our results are consistent with previous
reports which have found that prescriptions are predominantly
written using brand names.
3,4
Table 1. Use of Brand Versus Generic Names for Commonly Prescribed Medications






Status in 2003† Number of Years of
Generic Competition
Before 2003
Atorvastatin (Lipitor) 34.3 98% Brand –
Azithromycin (Z-pack, Zithromax) 17.0 98% Brand –
Rofecoxib (Vioxx) 15.6 100% Brand –
Amlodipine (Norvasc) 15.6 99% Brand –
Fluticasone (Flonase, Flovent, Cutivate) 14.5 100% Brand –
Cetirizine (Zyrtec) 13.8 100% Brand –
Celecoxib (Celebrex) 13.5 100% Brand –
Sertraline (Zoloft) 12.8 100% Brand –
Fexofenadine (Allegra) 12.2 100% Brand –
Escitalopram (Lexapro) 9.7 100% Brand –
Ciprofloxacin (Cipro, Cipro XR, Ciloxan) 7.7 92% Brand –
Clarithromycin (Biaxin, Biaxin XL) 6.9 100% Brand –
Metoprolol (Lopressor, Toprol XL) 20.0 78% Brand + Generic‡ 10‡
Amoxicillin (Amoxil, Sumox) 23.7 35% Generic >20
Levothyroxine (Unithroid, Levothyroid, Synthroid, Levoxyl, Levothyroid) 23.8 98% Generic >20§
Albuterol (Proventil, Ventolin, Volmax) 21.7 13% Generic 14
Prednisone (Sterapred DS, Deltasone) 14.3 0% Generic >20
Triamcinolone (Azmacort, Aristocort Kenalog, Triam, Triamolone 40, Nasacort) 10.9 81% Generic >20
Fluoxetine (Prozac, Sarafem) 10.4 80% Generic 2
Cephalexin (Keflex) 8.6 90% Generic 16
*Brand names cited by surveyed office practices
†Generic competition available in 2003 versus only brand-name formulations available
‡Metoprolol tartate (Lopressor, a short-acting form) had generic competition before 2003, but metoprolol succinate (Toprol XL, a longer-acting form)
remained under exclusivity protection at the time of the study. In comparative analyses, we classified metoprolol as a generically available drug.
Alternative classifications produced similar results.
§Although formulations of levothyroxine received FDA approval starting in 2000, in practice many formulations have been on the market for decades.
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Brand names are often more memorable or evocative than
generic names and easier to pronounce (in our sample, brand
names had on average 1.5 fewer syllables than their generic
counterparts).
7 Many physicians may be familiar only with the
brand name of certain drugs or unaware of the correspondence
between generic and brand names.
8–10 In addition, in certain
cases physicians may believe that generic formulations are not
as effective as the brand name product.
11 Although the
interchangeability of certain drugs remains a matter of
debate,
12 many physicians may not be aware of the strict
controls imposed by FDA to prove bioequivalence before a
generic formulation can be approved.
13
The use of brand names has substantial economic con-
sequences.
14,15 Pharmacist substitution of generic equivalents
is generally allowed and is encouraged by third party payers,
and several programs have been developed to encourage
generic substitution.
1,16 However, generic substitution is not
mandated in most states, can be overridden by the prescribing
physician and does not universally occur even when allowed
by the physician.
3,4 Overall, 39% of drugs available as generics
were filled with the brand formulation in a recent national
study.
1 As brand name drugs usually retain a substantial price
premium even after generic equivalents are introduced,
17
persistent use of brand name products has resulted in billions
of dollars of excess spending.
1
The use of brand names also has consequences for com-
munication between physicians. Confusion over drug termi-
nology can result in adverse drug events. For example, a
patient may inadvertently be given a second formulation of a
drug because the prescribing physician failed to recognize that
the patient was already taking the medication under a different
name.
18,19 In addition, use of brand names in communication
between physicians can undermine efforts to minimize com-
mercial influence on medical practice.
The use of brand names may reflect habitual use of a lexicon
learned in training or shortly after introduction of new drugs.
11
Therefore, efforts to increase the use of nonproprietary names
should focus on these periods of early exposure. Medical
students and residents should be educated about these issues,
and physician supervisors should be encouraged to promote
use of generic terminology in their day-to-day interactions with
trainees. Standards in continuing medical education programs
could also be strengthened: while the Accreditation Council for
Continuing Medical Education (ACCME) encourages the use of
generic names in educational presentations, parts of their
guideline place greater emphasis on balancing the use of
brand names across different companies than on minimizing
the use of proprietary terminology.
20 Electronic prescribing
systems could also be engineered to convert brand to generic
names. One place to start would be the official Medicare
Prescription Drug Plan Finder website (http://plancompare.
medicare.gov/drugselect.asp), which recognizes only brand
names for drugs that are currently under patent and exclu-
sivity protection.
Our study has several limitations. First, data were collected
from research forms. We cannot determine whether physicians
used the same terminology in their daily speech or when
writing prescriptions. Similarly, we do not know to what extent
use of brand name terminology reflected preference for specific
brand formulations (e.g., for a specific brand of levothyroxine).
Second, the majority of data forms were completed by office
staff and survey field personnel. However, subsidiary analyses
showed a similar distribution of brand and generic name use
whether a physician or nonphysician completed the form.
Third, our method for determining when generic competition
first became available does not fully capture the complex
approval histories for different formulations of the same drug.
Finally, our list of drugs was dominated by agents that had no
generic competition, limiting our ability to delineate terminol-
ogy patterns among drugs with generic competition.
Physicians’ preference for brand names may result in higher
health care costs and use of branded products where bioequiv-
alent alternatives are available. The use of nonproprietary
terminology in medicine should be encouraged to save costs,
limit commercial influence, and reduce the potential for
prescribing errors.
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